claim: treatment with an anti-ck2 synthetic peptide inhibited clinical response in covid-19 patients with pneumonia.
evidence_1: implications: our preliminary findings suggest that this anti-ck2 clinical approach could be combined with standard-of-care in covid-19 thus warranting larger studies.